The effects of anethum graveolens (dill) powder supplementation on glycemic control, lipid profile, some antioxidants and inflammatory markers, and gastrointestinal symptoms in type 2 diabetic patients: a double-blind, placebo-controlled trial

Fatemeh Haidari
Ahvaz Jondishapour University of Medical Sciences

Mehmoosh Zakerkish
Ahvaz Jondishapour University of Medical Sciences

Fatemeh Borazjani
Ahvaz Jondishapour University of Medical Sciences

Kambiz Ahmadi Angali
Ahvaz Jondishapour University of Medical Sciences

Golnaz Amoochi (✉ golnazamoochi@gmail.com)
Ahvaz Jondishapour University of Medical Sciences

Research

Keywords: Type 2 diabetes; Dill powder; Glycemic control; Lipid profile; Stress oxidative status

Posted Date: July 31st, 2019

DOI: https://doi.org/10.21203/rs.2.12262/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Trials on June 5th, 2020. See the published version at https://doi.org/10.1186/s13063-020-04401-3.
Abstract

Background: The objective of this study was to investigate the effects of anethum graveolens (dill) powder supplementation on glycemic control, lipid profile, some antioxidants and inflammatory markers, and gastrointestinal symptoms in type 2 diabetic patients. Material and methods: In this study, 42 type 2 diabetic patients were randomly allocated to intervention and control groups and received either 3 gr dill powder or placebo (3 capsules 1 gr) three per day. Fasting blood sugar (FBS), insulin, homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile, hs-C-reactive protein (hs-CRP), total antioxidant capacity (TAC), malondialdehyde (MDA) and gastrointestinal symptoms were measured in all subjects at baseline and post-intervention. Results: The dill powder supplementation significantly decreased the mean serum levels of insulin, HOMA-IR, LDL-C and MDA in the intervention group in compare with baseline (p < 0.05). Also, the mean serum levels of HDL and TAC was significantly increased in the intervention group in compare with baseline (p < 0.05). Colonic motility disorders was the only gastrointestinal symptom that its frequency was significantly reduced by supplementation (P = 0.01). The mean changes of insulin, LDL-c and MDA were significantly lower in intervention group in compare with control group (p < 0.05). In addition, the mean changes of HDL was significantly higher in intervention group in compare with control group (p < 0.05). Conclusion: It is recommended that dill powder supplementation may be effective in control of the glycemic, lipid, stress oxidative and gastrointestinal symptoms in type 2 diabetic patients.

Introduction

Diabetes is a public health problem affecting 285 million adults, in 2010, and will increase to 7.7% and 439 million adults by 2030 (1). In Iran, it has been estimated that 8% of adult population have diabetes (2). Major characteristic features of type 2 diabetes mellitus (T2DM) are obesity, impaired insulin action, insulin secretory dysfunction and increased endogenous glucose output (3). Increased free fatty acid flux secondary to insulin resistance is associated with diabetic dyslipidemia including high plasma triglyceride concentration and low HDL cholesterol concentration (4). Moreover, inflammatory cytokines contribute to T2DM occurrence by affecting beta cell function, and is in turn promote long-term complications of diabetes by intensifying hyperglycemia (5). Increased glucose uptake by endothelial cells in hyperglycemic conditions also leads to increased production of free radicals, which decrease levels of antioxidants (6). Besides, it is commonly reported that patients with T2DM are involved in gastrointestinal complications including gastro-esophageal reflux disease (GERD), gastroparesis, enteropathy, nonalcoholic fatty liver disease (NAFLD) and glycogenic hepatopathy (7).

Anethum Graveolens L, known as Dill, is a commonly used herb as a remedy and spices in foods (8). It is growing in the Mediterranean region, Europe, central, southern Asia and widely cultured in southeastern region of Iran (9). Anethum Graveolens (AG) leaves are a source of minerals, proteins and fibers (10). AG oils are also the potential source of antioxidant and also have antimicrobial and antispasmodic properties (11). In the traditional herbal medicine, AG is used for some gastrointestinal ailments such as indigestion and flatulence (12). AG has been established to have anticancer, antimicrobial, antigastric
irritation, anti-inflammatory, and antioxidant properties (13). In diabetic models, administration of different extractions of AG seed had antioxidant, hypolipidemic, and hypoglycemic effects (14). Earlier studies reported controversial findings for the protective effect of AG on lipid profile and insulin resistance in patients with metabolic syndrome (15, 16). Randomized clinical trials showed that AG reduced total cholesterol (5) and low density lipoprotein cholesterol (LDL-C), while did not change triglyceride and high density lipoprotein cholesterol (HDL-C) in patients with type 2 diabetes mellitus (T2DM) (17). It is also reported that AG could have beneficial effects on some inflammatory biomarkers (18), and controversial effects on glucose and insulin (18, 19). Besides inconclusive results considering glycemic, lipid and inflammatory profile, it is not clear whether AG help improve antioxidants and gastrointestinal symptoms. Therefore, the present study was designed to examine the effects of AG powder on serum levels of glycemic parameters, lipid profile, some antioxidants, inflammatory markers and gastrointestinal symptoms in patients with type 2 diabetes.

Materials And Methods

Study design and Participants

In this double-blinded (participants and investigator), placebo-controlled and single center trial 100 Type 2 diabetes patients were recruited from endocrinology and metabolism clinics of Golestan Hospital of Ahvaz Jundishapur University of Medical Science, Iran in 2017-2018 (Fig 1).

Inclusion criteria: Patients with DM (no more than five years since diagnosis); aged 30-60 years; with gastrointestinal symptoms; body mass index (BMI) range between 25 to 35 kg/m2; without systemic diseases, thyroid disease, kidney disorder; not pregnant and lactating women; were not taking any dietary supplements or antioxidants, and immunosuppressant and anti-inflammatory agents. Exclusion criteria: Noticeable change in the dose of medications and treatment of diabetes, the ones were refusing to continue the participation in the study, and the subjects who had less than 90% compliance with dill capsules.

Diagnosis of DM was done based on the American Diabetes Association guidelines. Patients with FBS $\geq 126$ mg/dl or 2-hour glucose $\geq 200$ mg/dl or HbA1c $\geq 6.5$% were diagnosed as diabetes mellitus (20).

Fifty two patients were excluded from study (because of not meeting inclusion criteria such as gastrointestinal symptoms and not accepting to participate). Forty eight patients were randomly assigned to two groups of intervention ($n = 24$) or placebo ($n = 24$), for 8 weeks. Randomization was done using the computer-generated random numbers by a third person to reduce the bias. The third person were generated a random block in blocks of 4. The naming of Dill or placebo bottles were done according to random numbers. odd or even numbers were allocated randomly to groups A or B. Multi-part questionnaire including demographic data (age and sex), anthropometric indices, dietary intake, medication, diabetes duration (in years), physical activity, gastrointestinal symptoms was obtained from subjects. During each visit, every patient was given dill supplement or placebo for 4 weeks and
throughout these weeks, consumption of supplements or placebo by the patients was ensured through phone calls or text messages. The compliance of patients was checked by counting the capsules remaining. Patients were excluded from study if had consumed less than 90% of prescribed capsules. The protocol of this study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (Ethical Code: IR.AJUMS.REC.1396.623) and this study was registered in the Iranian Registry of Clinical Trials website (IRCT20120704010181N12) which is available at: http://irct.ir/user/trial/20288/view. Written informed consent was obtained from all participants.

**Supplement and placebo prescription**

After confirmation the Anethum Graveolens (dill) herb by the botanist, dried leaves were milled to powder. Capsules containing 1 g of dill powder were provided by the Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. In this study, starch was used as placebo. The intervention and control groups received either 3 capsules of 1 gr dill or placebo three times per day after each meal (breakfast, lunch and dinner) for 8 weeks. The placebo and dill capsules were matched with together in terms of size, taste, color and shape.

**Assessment of demographic data, anthropometric indices and food intake**

Dietary intakes were investigated with a 24-h food recall for 3 days (2 week days and 1 weekend day), and dietary intake was analyzed by software Nutritionist 4 specified for Iranian foods. Anthropometric indices (weight, height, BMI) were measured by a trained researcher (nutritionist) at baseline and after the 8-week intervention. Weight (Seca, Germany) was measured while the patients wore light clothing and no shoes with 0.1-kg accuracy for weight. Height was measured using a stadiometer (Seca) with 0.5-cm accuracy without shoes. BMI was calculated (weight in kilogram divided by the square of the height in meter). Physical activity level was evaluated by the Persian and short form of the International Physical Activity Questionnaire (IPAQ) and presented in Met-Min/week. The participants were asked not to change their ordinary dietary intake and physical activity during the intervention.

**Assessment of gastrointestinal symptoms**

The assessment of gastrointestinal symptoms was done by questionnaire at the baseline and end of the study (21). This questionnaire was included gastrointestinal symptoms such as gastroesophageal reflux, esophageal motility disorders, dyspepsia, gastric motility disorders and colonic motility disorders.

The numbers 0, 1 and 2 indicate the severity of gastrointestinal symptoms. 0: the patient hadn't gastrointestinal symptoms, 1: patient had occasional gastrointestinal symptoms, and 2 ≤: the patient had permanently gastrointestinal problems.

**Biochemical assays**

Fasting blood samples (5 ml) were collected from all participants at the beginning and end of the study and were immediately centrifuged (3000×g, 10 min, 4°C). Blood samples were poured into anticoagulant
tubes in order to extract serum samples and sent to the lab in cool boxes. All samples were stored at − 70 °C until biochemical analyses. Serum glucose, TG, HDL and TC was measured by the standard enzymatic methods using Pars Azmoun kit (Tehran, Iran). Serum insulin was measured by human insulin enzyme-linked immunosorbent (ELISA) kit (mombind). Insulin resistance was estimated according to the Homeostasis Model Assessment (HOMA) calculated as: HOMA-IR = fasting concentrations of glucose (mg/dL) × fasting insulin (μU/mL) / 405 (22). Friedewald formula was used for calculation of LDL (23):

\[
LDL-c (mg/dL) = TC (mg/dL) - HDL-c (mg/dL) - \frac{TG (mg/dL)}{5} (VLDL),
\]

VLDL = \frac{TG (mg/dL)}{5}

Serum markers of oxidative stress such as total antioxidant capacity (TAC) and malondialdehyde (MDA) were measured by reliable spectrophotometric methods using Zell Bio GmbH kit (Germany). Serum levels of hc-CRP were measured by enzyme-linked immunosorbent assay (ELISA) kits (Diagnostics monobind).

**Sample size calculation**

The sample size (95% confidence interval and 80% power) was computed according to Mobasseri and coworkers’ study (24) and considering LDL-C as the main outcome. Sample size was 21 subjects for each group. 24 subjects were computed in per group with withdraw 10%.

**Outcomes**

In this study, LDL-C was considered as the primary outcome. Also, the secondary outcomes measurements were glycemic parameters, other factors of lipid profile, some antioxidant and inflammatory markers and gastrointestinal symptoms.

**Statistical analysis**

All statistical analysis was performed using SPSS 25. All data were reported as mean ± standard deviations (SD) for quantitative variables or number (percentage) for qualitative variables. Normal distribution of data was checked using Kolmogorove-Smirnov test. Paired sample t-test was also used to compare the results within groups post-intervention. Independent sample t-test was done to compare the results between the two groups (placebo and intervention). Also, Independent T-test was used to identify differences between two groups at the end of study. Analysis of covariance (ANCOVA) was used to identify any differences between two groups at the end of study, adjusting for baseline values and covariates. Also, Chi square test was done for statistical analysis of qualitative variables. P-value of less than 0.05 was considered statistically significant in all analyses.

**Results**

**Baseline characteristics of the subjects, anthropometric parameters, energy, macro and micro nutrient intakes**
42 diabetic patients (intervention group n = 21; control group = 21) for 8 weeks completed the study. The mean age of patients in the intervention and control groups was 50.66 ± 8.22 and 50.42 ± 8.61 years, respectively. No significant differences (P ≥ 0.05) were observed in demographic and anthropometric characteristics, duration of diabetes, physical activity and medications between the two groups at baseline (Table 1). No significant differences were also seen between the two groups for dietary intake including energy, macronutrients and micronutrients such as antioxidant vitamins C and E at baseline and after the intervention (P ≥ 0.05) (Table 2).

**Glycemic control**

The results of this study showed that no significant differences were seen in FBS, insulin and HOMA-IR between 2 groups at baseline (P ≥ 0.05). It was demonstrated that 8 weeks consumption of dill powder significantly decreased the mean serum levels of insulin and HOMA-IR in the intervention group in compare with baseline (13.27 ± 3.8 vs 10.54 ± 4.51 µU/ml, respectively; P = 0.004), HOMA-IR (4.88 ± 2.37 vs 3.86 ± 2.32, respectively; P = 0.039). Furthermore, the mean changes of insulin was significantly (P= 0.012) lower in the intervention group in compare with control group after the intervention (-2.7 ± 3.83 vs -0.81 ± 6.26, respectively; P = 0.015). Analysis of covariance (ANCOVA) showed that after the adjusting of confounding factors (age, duration of disease, changes of body mass index, dietary intake of energy, macronutrients, Vitamin A, C, and E, and physical activity), the mean changes of insulin were significantly (P= 0.05) lower in the intervention group in compare with control group after the intervention (Table 3).

**Lipid profile**

At baseline, there were no significant differences in the mean serum levels of TG, TC, LDL-C and HDL between two groups (P > 0.05). The dill powder supplementation significantly increased the mean serum levels of HDL in the intervention group in compare with baseline (41.85 ± 11.68 to 44.80 ± 9.89 mg/dl, respectively; P = 0.007). Also, the mean changes of serum levels of HDL were significantly higher in the intervention group in compare with the control group (2.59 ± 4.51 vs -1.38 ± 4.60 mg/dl, respectively; P = 0.004). Even after the adjusting of confounding factors, there was a significant difference in mean change of HDL-C between two groups (P = 0.04). In the intervention group, it was shown that the mean serum level of LDL-C was significantly decreased post-intervention (81.00 ± 34.79 to 71.23 ± 26.63 mg/dl, respectively; p = 0.029). Furthermore, the mean changes of serum levels of LDL-C were significantly lower in the intervention group in compare with the control group (-9.76 ± 19.08 vs 3.09 ± 14.07 mg/dl, respectively; P = 0.017). After the adjusting of confounding factors, there was a significant difference in mean change of LDL-C between two groups (P = 0.04). However, no significant changes were seen in the mean serum levels of TG and TC after the intervention (P ≥ 0.05) (Table 3).

**Antioxidant and inflammatory markers**

According to the analysis, there were no significant differences in the mean serum levels of hs-CRP, MDA and TAC between two intervention and control groups at the baseline (P ≥ 0.05). The results of present study showed that in intervention group the mean of MDA was reduced significantly post-intervention in
compare with baseline (3.34 ± 2.05 to 2.22 ± 1.57 μM, respectively; P = 0.034). At the end of study, there was significantly difference in the mean changes of MDA between intervention and control groups without and with the adjusting of confounding factors (-1.11 ± 2.24 vs 0.33 ± 1.62 μM, respectively; P = 0.021 vs P = 0.013, respectively). Within group comparison in the intervention group showed that the mean serum levels of TAC significantly increased after 8 weeks of supplementation (0.19 ± 0.05 to 0.25 ± 0.09 mM, respectively; p=0.025). In addition, after the supplementation, the mean serum levels of TAC were significantly higher in the intervention group in compare with the control group (0.25 ± 0.09 vs 0.16 ± 0.06 mg/dl, respectively; P = 0.001). This result for TAC was also seen after the adjusting of confounding factors (P = 0.004). No significant difference was observed for hs-CRP within and between two groups (P ≥ 0.05) (Table 4).

Gastrointestinal symptoms

Based on the results presented in table 5, supplementation with dill failed to reduce the frequency of gastrointestinal symptoms such as gastroesophageal reflux, esophageal motility, dyspepsia and gastric motility disorders in compare with baseline (P ≥ 0.05). Colonic motility disorders was the only gastrointestinal symptom that its frequency was significantly reduced by supplementation (P = 0.01), and this decrease had more happened in patients who had more severe gastrointestinal problems. However, in the control group, there was no significant reduction in the frequency of the gastrointestinal symptoms (P ≥ 0.05).

Discussion

The present study revealed that 8 weeks of supplementation with 3 g/day AG had beneficial effects on reducing serum insulin and HOMA-IR. Moreover, AG could significantly reduce serum levels of LDL and enhance HDL compared with placebo. Patients in the intervention group had lower MDA and TAC; however, no significant change was observed for serum levels of hs-CRP. In terms of gastrointestinal symptoms, colonic motility disorders were only decreased.

The present findings are in line with those of several interventional studies confirming the benefits of AG in T2DM and metabolic syndrome (14, 25). The findings of significant reduction in HOMA-IR and serum levels of insulin which indicate that AG has a role in reducing insulin resistance. Similar beneficial effects of AG on glycemic control have been reported previously. Supplementation of T2DM patients with 3.3 g/day powder of Anethum for 8 weeks could significantly reduce levels of insulin (17). After 6 weeks of supplementation with 1.5 g/day dill powder tablets, serum levels of FBS were significantly reduced in patients with T2DM (19). Although Payahoo et al. (18) found a significant decrease in serum levels of insulin, no significant effect was observed for HOMA-IR which could be due to reduced levels of FBS in diabetic patients. High content of antioxidants (i.e. vitamin C, polyphenols, and carotenoids) in AG neutralize reactive oxygen species, and therefore, have a role in repairing of beta cells function and insulin secretion (26, 27).
In present study, serum concentrations of LDL decreased and HDL increased significantly at the end of the study. Whereas, no significant change was seen for serum levels of TG and TC. In agreement with our study, Rashidlamir et al. (28) showed that aerobic training with usage of 900 mg/day AG resulted in increased HDL and decreased LDL to HDL ratio in diabetic women compared with control group; however, findings from TG and TC was not statistically significant. In contrast, supplementation with 650 mg/d Anethum tablets twice daily increased serum levels of TG in patients with hyperlipidemia, but no significant changes were seen in TC and LDL (29). Treatment of hyperlipidemic patients with 1 g/day AG leave powder for 4 weeks duration resulted in a significant reduction in the levels of TC, TG, LDL and VLD compared with patients treated with 20mg/day lovastatin tablets; however, no significant change was observed in serum levels of HDL. The exact mechanism of lipid-lowering effects of AG is not yet determined. But it may refer to decreased absorption of cholesterol by binding to bile acids, inhibition of cholesterol and fatty acid synthesis through suppression of acetyl-CoA carboxylase and HMG-CoA reductase activity, and stimulating cholesterol clearance by increasing LDL receptors (30-32).

In the current study, compared with patients in the control group, those received 3 g/day AG had lower levels of MDA and higher levels of TAC in both crude and adjusted models. MDA is a final product of lipid peroxidation recognized as an atherogenic agent. Patients with elevated levels of MDA are more susceptible to atherosclerosis, diabetes, and other metabolic disorders (33). Findings from animal studies showed that administration of different fractions of AG in animals fed with a high-fat diet decreased the MDA levels, and increased the activities of antioxidant enzymes including superoxide dismutase (SOD) and catalase. It is further increased the level of glutathione (GSH) plate a key role in scavenging ROS (34). Hamsters treated with AG extract or tablet exhibited a significant rise in TAC level compared with those under high cholesterol diet (35). AG is composed of various content of antioxidant such as flavonoids capable of scavenging free radicals (36). The enhanced levels of antioxidant activities in response to AG might be due to the content of polyphenols and flavonoids. Normal levels of antioxidant is supposed to protect individuals against several chronic diseases (37).

We observed non-significant decrease in serum levels of hs-CRP after supplementation with AG. The fact that an increase in the body weight is an indicator of inflammation (38) may be the reason of non-significant reduction observed in serum levels of hs-CRP in our study. Anti-inflammatory effects of different forms of AG have been shown in several animal studies (39-41). Payahoo et al. (18) found a significant decrease in serum levels of inflammatory biomarkers including hs-CRP, IL-6, and TNF-α after 8 weeks of supplementation with 3.3 gram dill powder.

In terms of gastrointestinal symptoms, we only observed a significant decrease in colonic motility disorders. It is reported that the most prevalent symptoms among diabetic patients are colonic motility disorders, which increase with age (42). Moreover, the prevalence of gastrointestinal symptoms is positively associated with duration of diabetes (42, 43). Patients included in the current study had a mean age of 50 years and a mean disease duration of 8 years which are relatively high, which could be a reason for the observed findings in this regard. Earlier animal models showed that AG extract is a potent
relaxant of contractions in rat ileum and have antisecretory and anti-ulcer activity against HCl- and ethanol-induced stomach lesions (44, 45).

To the best of our knowledge, this is the first human study investigating the effects of AG on gastrointestinal symptoms. The major strength of the present study was designing a well-controlled double-blind clinical trial, with controlling for several main confounding factors in different models. There are some limitations to our study. First, this is a single-dose trial preventing from any dose-effect association. It remains unclear whether higher doses could introduce a stronger clinical effect or vice versa. Second, the narrow range of inclusion criteria lead to unrepresentative samples that limit generalizability of the study results to all diabetic patients.

**Conclusion**

In conclusion, the present study suggests beneficial effects of AG in insulin resistance, LDL and HDL cholesterol, antioxidant levels, and some gastrointestinal symptoms compared with placebo during 8 weeks of supplementation. Further studies are needed to determine molecular levels and clarify its role in the treatment of diabetes complications.

**Abbreviations**

Fasting blood sugar (FBS), gastro-esophageal reflux disease (GERD), high-density lipoprotein (HDL), homeostatic model assessment of insulin resistance (HOMA-IR), hs-C-reactive protein (hs-CRP), low-density lipoprotein (LDL), malondialdehyde (MDA), non-alcoholic fatty liver disease (NAFLD), total antioxidant capacity (TAC), total cholesterol (TC), triglyceride (TG).

**Declarations**

**Acknowledgements**

Present study is resulted from the M.Sc thesis of MS Amoochi. The authors would like to thank the Nutrition and Metabolic Diseases Research Center, Research Center for Diabetes and Endocrinology and Metabolism clinic employees of Golestan Hospital of Ahvaz Jundishapur University of Medical Sciences.

**Author contribution**

Amoochi G, Haidari F concepted the idea and designed the study. Amoochi G and Zakerkish M collected the data. Haidari F and Ahmadi Angali K analyzed and interpreted the results. Amoochi G, Haidari F and Borazjani F drafted the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was financially supported by Vice-Chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences (NRC-9617).
Availability of data and materials

The results will not be available before publishing.

Ethics approval and consent to participate

The protocol was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (Ethical Code: IR.AJUMS.REC.1396.623) that is in accordance with the Declaration of Helsinki. Each participant will sign an informed consent form.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010 Jan;87(1):4-14. PubMed PMID: 19896746. Epub 2009/11/10. eng.

2. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes care. 2008 Jan;31(1):96-8. PubMed PMID: 17921357. Epub 2007/10/09. eng.

3. Rosal MC, Borg A, Bodenlos JS, Tellez T, Ockene IS. Awareness of diabetes risk factors and prevention strategies among a sample of low-income Latinos with no known diagnosis of diabetes. The Diabetes educator. 2011 Jan-Feb;37(1):47-55. PubMed PMID: 21220363. Epub 2011/01/12. eng.

4. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice Endocrinology & metabolism. 2009 Mar;5(3):150-9. PubMed PMID: 19229235. Epub 2009/02/21. eng.

5. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Current diabetes reports. 2013 Jun;13(3):435-44. PubMed PMID: 23494755. Epub 2013/03/16. eng.

6. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of clinical investigation. 2005;115(5):1111-9. PubMed PMID: 15864338. eng.

7. Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World journal of diabetes. 2013;4(3):51-63. PubMed PMID: 23772273. Epub 2013/06/15. eng.

8. Saleh-E-In MM, Sultana N, Rahim MM, Ahsan MA, Bhuiyan MNH, Hossain MN, et al. Chemical composition and pharmacological significance of Anethum Sowa L. Root. BMC complementary and
alternative medicine. 2017;17(1):127-. PubMed PMID: 28231789. eng.
9. V. M. Dictionary of Iranian plant names. Tehran, Iran. Farhang Moaser Publications. 1995:44.
10. Rekha MN YA, Dharmesh Sh, Chauhan AS, Ramteke RS. Evaluation of Antioxidant properties of dry soup mix extracts containing Dill (Anethum sowa L.) leaf. Food Bioprocess Technol 2010;3:441-449.
11. Singh G, Maurya S, De Lampasona M, Catalan CJ. Chemical constituents, antimicrobial investigations, and antioxidative potentials of Anethum graveolens L. essential oil and acetone extract: Part 52. 2005;70(4):M208-M15.
12. NJ: HDM. PDR for herbal medicines. Thomson. 2004:650–1. English.
13. Oshaghi EA, Khoddadi I, Tavilani H, Goodarzi MT. Effect of dill tablet (Anethum graveolens L) on antioxidant status and biochemical factors on carbon tetrachloride-induced liver damage on rat. International Journal of Applied and Basic Medical Research. 2016;6(2):111.
14. Goodarzi MT, Khoddadi I, Tavilani H, Abbasi Oshaghi E. The Role of Anethum graveolens L. (Dill) in the Management of Diabetes. Journal of tropical medicine. 2016;2016:1098916. PubMed PMID: 27829842. Pubmed Central PMCID: PMC5088306. Epub 2016/11/11. eng.
15. Kojuri J, Vosoughi AR, Akrami M. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients. Lipids in Health and Disease. 2007;6(1):5.
16. Mansouri M, Nayebi N, Hasani-Ranjbar S, Taheri E, Larijani B. The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial. DARU Journal of Pharmaceutical Sciences. 2012;20(1):47.
17. Mobasseri M, payahoo L, Ostadrahimi A, Khaje bishak Y, Asghari Jafarabadi M, Mahluji S. Anethum graveolens Supplementation Improves Insulin Sensitivity and Lipid Abnormality in Type 2 Diabetic Patients. 2014 2014/9/30 %J Pharm Sci;20(2):40-5.
18. Payahoo L K-BY, Mobasseri M, Ostadrahimi A, Asghari-Jafarabadi M. The Effects of Anethum Graveolens L Supplementation on the Insulin Resistance and Inflammatory Biomarkers in Patients with Type 2 Diabetes. JIMS 2015; 32(320): 2473-83.
19. Sargolzari MS MA, Shahdadi H, Masinaei Nezhad N, Poodineh Moghadam M. The effect of dill tablet on the level of fasting blood sugar in patients with type II diabetes. J Diabetes Nurs 2017;5(2):86-94.
20. Ta S. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014;37:S81.
21. Hashemi SJ, Arghideh M, Fardad F, Latifi SMJ. Metabolism. Prevalence of Gastrointestinal Symptoms in Type 2 Diabetic Patients and its Association with Glycemic Control and Duration of Diabetes. 2012;13(5):459-66.
22. Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, et al. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. Journal of gastroenterology and hepatology. 2019.
23. Moravej Aleali A, Amani R, Shahbazian H, Namjooyan F, Latifi SM, Cheraghian B. The effect of hydroalcoholic Saffron (Crocus sativus L.) extract on fasting plasma glucose, HbA1c, lipid profile,
liver, and renal function tests in patients with type 2 diabetes mellitus: A randomized double-blind clinical trial. Phytotherapy Research. 2019.

24. Mobasseri M, Payahoo L, Ostadrahimi A, Bishak YK, Jafarabadi MA, Mahluji S. Anethum graveolens supplementation improves insulin sensitivity and lipid abnormality in type 2 diabetic patients. Pharmaceutical Sciences. 2014;20(2):40.

25. Mansouri M, Nayebi N, Keshtkar A, Hasani-Ranjbar S, Taheri E, Larijani B. The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2012 Oct 4;20(1):47. PubMed PMID: 23351341. Pubmed Central PMCID: PMC3555834. Epub 2013/01/29. eng.

26. Agte VV, Tarwadi KV, Mengale S, Chiplonkar SA. Potential of Traditionally Cooked Green Leafy Vegetables as Natural Sources for Supplementation of Eight Micronutrients in Vegetarian Diets. Journal of Food Composition and Analysis. 2000 2000/12/01/;13(6):885-91.

27. Madani H, Ahmady Mahmoodabady N, Vahdati A. EFFECTS OF HYDROALCHOHOLIC EXTRACT OF ANETHUM GRAVEOLENS (DILL) ON PLASMA GLUCOSE AN LIPID LEVELS IN DIABETES INDUCED RATS. 2005.

28. Rashidlamir A, Gholamian S, Hashemi Javaheri SAA, Research MDJAoB. The effect of 4-weeks aerobic training according with the usage of Anethum Graveolens on blood sugar and lipoproteins profile of diabetic women. 2012.

29. Kojuri J, Vosoughi AR, Akrami M. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients. Lipids in health and disease. 2007;6:5-. PubMed PMID: 17328819. eng.

30. Yazdanparast R, Bahramikia S. Evaluation of the effect of Anethum graveolens L. crude extracts on serum lipids and lipoproteins profiles in hypercholesterolaemic rats 2008.

31. Piri M, Shahin M, Oryan S. The effects of Anethum on plasma lipid and lipoprotein in normal and diabetic rats fed high fat diets %J Journal of Shahrekord University of Medical Sciences. 2010;11(4):15-25. eng.

32. Haghighi B, Kharazizadeh M, Attar M. Possible Involvement of Hepatic Phosphatidate Phosphohydrolase in the Mechanisms of Actions of Certain Antilipemic Drugs in Rats %J Iranian Journal of Pharmaceutical Research. 2010;Volume 6(Number 4):273-8.

33. Bakhtiari A, Hajian-Tilaki K, Omidvar S, Nasiri Amiri F. Association of lipid peroxidation and antioxidant status with metabolic syndrome in Iranian healthy elderly women. Biomedical reports. 2017;7(4):331-6. PubMed PMID: 28928971. Epub 2017/08/09. eng.

34. Bahramikia S, Yazdanparast R. Efficacy of different fractions of Anethum graveolens leaves on serum lipoproteins and serum and liver oxidative status in experimentally induced hypercholesterolaemic rat models. The American journal of Chinese medicine. 2009;37(4):685-99. PubMed PMID: 19655407. Epub 2009/08/06. eng.

35. Abbasi-Oshaghi E, Khodadadi I, Tavilani H, Mirzaei F, Goodarzi MT. Dill-normalized liver lipid accumulation, oxidative stress, and low-density lipoprotein receptor levels in high cholesterol fed
36. Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2005 Nov 15;827(1):76-82. PubMed PMID: 16009604. Epub 2005/07/13. eng.

37. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clinical chemistry and laboratory medicine. 1999 Aug;37(8):777-87. PubMed PMID: 10536926. Epub 1999/10/28. eng.

38. Adebayo AH, Abolaji, A. O., Opata, T. K., and Adegbenro, I. K. . Effects of ethanolic leaf extract of Chrysophyllum albidum G. on biochemical and haematological parameters of albino Wistar rats. African Journal of Biotechnology. 2010;9:2145-50.

39. Valady A NS, Abbasi N. Anti-inflammatory and analgesic effects of hydroalcoholic extract from the seed of Anethum graveolens L. J Med Plants 2010; 9: 130-124.

40. Naseri M MF, Khodadoost M. The study of antiinflammatory activity of oil-based dill (Anethum graveolens L.) extract used topically in formalin-induced inflammation male rat paw. Iranian Journal of Pharmaceutical Research 2012; 11 (4): 1169-1174.

41. and TPA-induced mouse ear edema. Zhonghua Yaoxue Zazhi 1995; 47:421-430. OTeaSoe-\textunderscore conrXleosoTH-ciipoCHTc.

42. Shahbazian Hb, Hashemi SJ, Arghideh M, Fardad F, Latifi SM. Prevalence of Gastrointestinal Symptoms in Type 2 Diabetic Patients and its Association with Glycemic Control and Duration of Diabetes %J Iranian Journal of Endocrinology and Metabolism. 2012;13(5):459-66. eng.

43. Fujishiro M, Kushiyama A, Yamazaki H, Kaneko S, Koketsu Y, Yamamotoya T, et al. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World journal of gastroenterology. 2017 Sep 28;23(36):6694-704. PubMed PMID: 29085214. Pubmed Central PMCID: PMC5643290. Epub 2017/11/01. eng.

44. Naseri MG, Heidari AJJP. Antispasmodic effect of Anethum graveolens fruit extract on rat ileum. 2007;3(3):260-4.

45. Hosseinzadeh H, Karimi GR, Ameri M. Effects of Anethum graveolens L. seed extracts on experimental gastric irritation models in mice. BMC Pharmacol. 2002;2:21-. PubMed PMID: 12493079. eng.

Additional File

Additional file 1: Standard Protocol Items: Recommendations for Interventional Trials (CONSORT) 2010 Checklist: recommended items to address in a clinical trial protocol and related documents.
Figures

**Recruited subjects (n = 100)**
Providing consent form, tailoring questionnaire and subject information sheet

**Excluded (n = 52)**
- Not meeting criteria
- Declined to participate

**Allocation (n = 48)**

**Intervention group (n = 24)**
- Baseline visit: Assessing the anthropometric indices and gastrointestinal symptoms and blood collection
- Excluded (n = 3)
  - 2 discontinue intervention
  - 1 never received supplementation

**Control group (n = 24)**
- Baseline visit: Assessing the anthropometric indices and gastrointestinal symptoms and blood collection
- Excluded (n = 3)
  - 1 discontinue intervention
  - 2 never received placebo

**8 weeks visit**
Received 3 capsules of dill or placebo (3gr) three time per day after each meal (breakfast, lunch and dinner) for 8 weeks, end of intervention due to completion of supplementation duration according to other studies and financial limitation. Assessing the anthropometric indices and blood collection

**Analysis**
Laboratory analysis including FBS, Insulin, HOMA-IR, lipid profile, assessment of anthropometric indices, gastrointestinal symptoms and analysis by ELISA including serum levels of hs-CRP, MDA and TAC

**Figure 1**
Stages of clinical trial progress

**Supplementary Files**
This is a list of supplementary files associated with this preprint. Click to download.

- supplement1.pdf
- supplement2.pdf